Maia Biotech completes Phase 2 enrollment for THIO-101 ateganosine plus cemiplimab

Maia Biotechnology said Phase 2 enrollment is complete for the ateganosine plus cemiplimab cohort in THIO-101, with THIO-104 Phase 3 enrollment at 65% of a 100-patient year-end goal; an interim analysis is planned for 2027.